Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PSCK9 Battle: Sanofi Not Negotiating Praluent Fate With Amgen; Ruling Possible By June

Executive Summary

Sanofi attorneys describe three possible outcomes of fight over injunction and validity of Repatha patents, and contrast litigation to other patent disputes where innovators did not seek removal of innovator product from market.

You may also be interested in...



Amgen Hit By Enbrel 'Peculiarities' And Repatha Resistance

Amgen reported a surprising double-digit decline for Enbrel during the first quarter and sales for the cholesterol-lowering biologic Repatha showed that the PCSK9 inhibitor is not going to make up for the company's declining revenue any time soon – at least not while payers continue to block its use.

What To Look Out For At ACC

Amgen has already reported the positive topline result of its FOURIER cardiovascular outcomes trial for its PCSK9 inhibitor Repatha, but analysts from Datamonitor Healthcare and Biomedtracker lay out the reasons to check out the full results and other highlights at the upcoming American College of Cardiology meeting.

Biosimilars Could Face 'Litigation Backlog' Without Patent Reforms, AAM Fears

Category is still in its infancy, but the newly renamed generic association worries that products might never reach their full potential if launches are substantially delayed by IP disputes.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS120028

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel